Contact | Print version | PDF version | Send article | RSS feed

Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA

10 Dec 2008 - Kiadis Pharma announces that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc™ Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc™ is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
 
"This is an important strategic milestone in the development of Reviroc™ and we are very pleased with the orphan drug designations received from the FDA”, says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.